# Characteristic α-Acid Derivatives from *Humulus lupulus* with Antineuroinflammatory Activities

Jiayuan Li,<sup>†</sup> Ning Li,<sup>\*,†</sup> Xuezheng Li,<sup>‡</sup> Gang Chen,<sup>†</sup> Cungang Wang,<sup>†</sup> Bin Lin,<sup>§</sup> and Yue Hou<sup>\*,⊥</sup>

<sup>†</sup> School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Wenhua Road 103, Shenyang 110016, People's Republic of China

<sup>\*</sup> Department of Pharmacy, Affiliated Hospital of Yanbian University, Yanji 133000, People's Republic of China

§ School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China

<sup>⊥</sup> College of Life and Health Sciences, Department of Biochemistry and Molecular Biology, Northeastern University, Shenyang, 110819, People's Republic of China

#### **List of Supporting Information**

**S1.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).

S2. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).

**S3.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).

S4. HMBC (600 MHz,  $CDCl_3$ ) spectrum of (3*R*, 8*S*)-humulone A (1).

**S5.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).

S6. HRESIMS spectrum of (3*R*, 8*S*)-humulone A (1).

S7. Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo

conformers of (3R, 8S)-1 based on experimental NOE correlations.

**S8.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3S, 8S)-humulone A (2).

**S9.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (**2**).

**S10.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (2).

**S11.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (2).

**S12.** NOESY (600 MHz,  $CDCl_3$ ) spectrum of (3*S*, 8*S*)-humulone A (2).

S13. HRESIMS spectrum of (3S, 8S)-humulone A (2).

**S14.** Experimental CD spectrum of (3*S*, 8*S*)-humulone A (2).

**S15.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3S, 8S)-cohumulone A (**3**).

**S16.** <sup>13</sup>C NMR(100 MHz, CDCl<sub>3</sub>) spectrum of (3S, 8S)-cohumulone A (3).

**S17.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (**3**).

**S18.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (**3**).

**S19.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (**3**).

**S20.** HRESIMS spectrum of (3*S*, 8*S*)-cohumulone A (**3**).

**S21.** Experimental CD spectrum of (3*S*, 8*S*)-cohumulone A (3).

**S22.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2S, 7S)-humulone B (4).

**S23.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-humulone B (4).

**S24.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 7S)-humulone B (4).

**S25.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-humulone B (4).

**S26.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 7S)-humulone B (4).

**S27.** HRESIMS spectrum of (2*S*, 7*S*)-humulone B (4).

S28. Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo

conformers of (2S, 7S)-4 based on experimental NOE correlations.

**S29.** <sup>1</sup>H NMR(400 MHz, CDCl<sub>3</sub>) spectrum of (2R, 7S)-humulone B (5).

**S30.** <sup>13</sup>C NMR(100 MHz, CDCl<sub>3</sub>) spectrum of (2R, 7S)-humulone B (5).

**S31.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (**5**).

**S32.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (5).

**S33.** NOESY (600 MHz,  $CDCl_3$ ) spectrum of (2R, 7S)-humulone B (5).

**S34.** HRESIMS spectrum of (2*R*, 7*S*)-humulone B (**5**).

**\$35.** Selected structures and population of the low-energy B3LYP/6-31G (d) in *vacuo* conformers of (2R, 7S)-**5** based on experimental NOE correlations.

**S36.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2S, 7S)-cohumulone B (6).

**S37.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).

**S38.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).

**S39.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).

**S40.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6)

**S41.** HRESIMS spectrum of (2*S*, 7*S*)-cohumulone B (6).

**S42.** Experimental CD spectrum of (2*S*, 7*S*)-cohumulone B (6).

**S43.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 3a*S*)-humulone C (7).

**S44.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 3aS)-humulone C (7).

S45. HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).

S46. HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).

S47. NOESY(600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).

**S48.** HRESIMS spectrum of (2*S*, 3*aS*)-humulone C (7).

**S49.** Structures and populations of the low-energy B3LYP/6-31G (d) in *vacuo* conformers (>2%) of (2*S*, 3a*S*)-7.

**S50.** <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S51.** <sup>13</sup>C NMR (150 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S52.** HSQC (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S53.** HMBC (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S54.** NOESY (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S55.** HRESIMS spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S56**. Selected structures and population of the low-energy B3LYP/6-31G (d) in *vacuo* conformers of (3S, 3'R)-8 based on experimental NOE correlations.

**S57.** The molecular energy profiles of conformational flexibility of compound **8** 

**S58.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).

**S59.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of (R)-lupulone H (**9a**).

**S60.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of (S)-lupulone H (**9b**).

**S61.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).

S62. HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).

**S63.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).

S64. NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).

**S65.** HRESIMS spectrum of lupulone H (9).

**S66.** The HPLC of chiral column analysis of lupulone H (9).

**S67.** Structures and populations of the low-energy B3LYP/6-31G (d) in *vacuo* conformers (>2%) of (2*S*)-9.

**S68.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of lupulone G (10)

**S69.** <sup>1</sup>H NMR (600 MHz, DMSO- $d_6$ ) spectrum of (*R*)-lupulone G (10a)

**S70.** <sup>1</sup>H NMR (600 MHz, DMSO- $d_6$ ) spectrum of (S)-lupulone G (10b)

**S71.** <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of lupulone G (10).

**S72.** Experimental CD spectra of (*R*)-lupulone G (10a) and (*S*)-lupulone G (10b).

**S73.** The HPLC of chiral column analysis of lupulone G (10).

**S74.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of 5-deprenyllupulonol C (11).

**S75.** <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of 5-deprenyllupulonol C (11).

**S76.** Experimental CD spectra of (R)-5-deprenyllupulonol C (**11a**) and (S)-5-deprenyllupulonol C (**11b**).

**S77.** The HPLC of chiral column analysis of 5-deprenyllupulonol C (11).

**S78.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).

**S79.** <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (**12**).


**S80.**HSQC(600MHz,DMSO- $d_6$ )spectrumof5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).**S81.**HMBC(600MHz,DMSO- $d_6$ )spectrumof

5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).

**S82.** HRESIMS spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).


**S83.** The experimental method used for ECD calculations of compounds 1, 4, 5, 7, 8 and 9.


S84. BV-2 cell viability assay and effect of the extracts and isolated compounds 1-8,13-17 on LPS-induced NO production in BV-2 microglial cells.



S1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).


**S2.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (3*R*, 8*S*)-humulone A (1).






**S3.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).

S4. HMBC (600 MHz,  $CDCl_3$ ) spectrum of (3*R*, 8*S*)-humulone A (1).






**S5.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (3R, 8S)-humulone A (1).


Analysis Info					rmula Repo			
Analysis into					Acquisition Date	3/12/20	)14 3:55:42	РМ
Analysis Name	D:\Data\20140312ceyang\HOPS14_1-c,6_01_2809.d							
Method	liu xioaqiu.m				Operator	Bruker	Customer	
Sample Name	HOPS14				Instrument / Ser#	# micrOT	OF-Q 12	5
Comment								-
Acquis	meter							
Source T	ESI		on Polarity	Positive	Set Nebuliz		1.2 Bar	
ocus	Active		et Capillary	4500 V	Set Dry Hea		180 °C	
ican Be	50 m/z		et End Plate Offset	-500 V	Set Dry Gas		8.0 l/min	
can End	1000 m/z	5	et Collision Cell RF	300.0 Vpp	Set Divert V	alve	Source	
Senerate Moleo ormula, min.	cular Formula P C21H20O6Na	arameter						
ormula, min. ormula, max.	021H2006Na							
leasured m/z	401.195		Tolerance	5 ppm	Charge	1		
heck Valence	no			0	Maximun			
lirogen Rule	no		Electron Config					
ilter H/C Ratio	no		Minimum	0	Maximun	n 3		
stimate Carbon	yes							
1.25 1.00 0.75				401.1950				
0.50								
0.25	332.1206		379.2096		433			
	332.1206	360	379.2096	400 4	433	460	490	,
0.25	320 340		380		20 440		480	-
0.25	320 340 Formula Sigm	a m/z	380		20 440 [mDa] rdb NRu		490	
0.25 0.00 300 Sum	320 340 Formula Sigm	a m/z	380 Err [ppm] Mean	Err [ppm] Err	20 440 [mDa] rdb NRu	ile e	490	· · ·
0.25 0.00 300	320 340 Formula Sigm	a m/z	380 Err [ppm] Mean	Err [ppm] Err	20 440 [mDa] rdb NRu	ile e	480	


## **S6.** HRESIMS spectrum of (3R, 8S)-humulone A (1).

**S7.** Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo conformers of (3R, 8S)-1 based on experimental NOE correlations.




**S8.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (2).






**S9.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (**2**).


**S10.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (**2**).






**S11.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (2).


S12. NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-humulone A (2).




### **S13.** HRESIMS spectrum of (3*S*, 8*S*)-humulone A (2).




S14. Experimental CD spectrum of (3*S*, 8*S*)-humulone A (2).




**S15.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (3S, 8S)-cohumulone A (3).






**S16.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (3).


S17. HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (3).






**S18.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (**3**).


**S19.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (3*S*, 8*S*)-cohumulone A (**3**).





#### **S20.** HRESIMS spectrum of (3*S*, 8*S*)-cohumulone A (**3**).




**S21.** Experimental CD spectrum of (3*S*, 8*S*)-cohumulone A (3).











**S23.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-humulone B (4).


**S24.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-humulone B (4).






**S25.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-humulone B (**4**).

S26. NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 7S)-humulone B (4).





#### **S27.** HRESIMS spectrum of (2*S*, 7*S*)-humulone B (4).



S28. Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo


conformers of (2S, 7S)-4 based on experimental NOE correlations.






**S29.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2R, 7S)-humulone B (5).


**S30.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (**5**).







**S31.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (**5**).

**S32.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (**5**).






**S33.** NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (2*R*, 7*S*)-humulone B (**5**).




#### **S34.** HRESIMS spectrum of (2*R*, 7*S*)-humulone B (5).


S35. Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo


conformers of (2R,7S)-5 based on experimental NOE correlations.




Conf. A 28.4 %











**S36.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).


**S37.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).






**S38.** HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).


**S39.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6).






S40. NOESY (600 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 7*S*)-cohumulone B (6)


#### **S41.** HRESIMS spectrum of (2*S*, 7*S*)-cohumulone B (6).




S42. Experimental CD spectrum of (2S, 7S)-cohumulone B (6).




S43.  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 3a*S*)-humulone C (7).






**S44.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of (2*S*, 3aS)-humulone C (7).


S45. HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).





S46. HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).


S47. NOESY(600 MHz, CDCl<sub>3</sub>) spectrum of (2S, 3aS)-humulone C (7).




#### Mass Spectrum Molecular Formula Report Analysis Info Acquisition Date 7/11/2014 3:14:56 PM D:\Data\20140711\HOPS31.d Analysis Name Liu\_low\_20131025.m HOPS31 Method Bruker Customer Operator Sample Name Instrument / Ser# micrOTOF-Q 125 Comment Acquisition Parameter Ion Polarity Set Capillary Set End Plate Offset Set Collision Cell RF Source Type Focus Scan Begin Scan End ESI Positive 4500 V -500 V 300.0 Vpp Set Nebulizer Set Dry Heater Set Dry Gas Set Divert Valve 0.3 Bar 180 °C 4.0 l/min Source Active 50 m/z 1000 m/z Generate Molecular Formula Parameter Formula, min. C21H30O6Na Formula, max. Measured m/z Check Valence Nirogen Rule Filter H/C Ratio Estimate Carbon Tolerance 5 ppm Minimum 0 Electron Configuration even Minimum 0 401.195 Charge Maximum 1 no yes yes yes Maximum 3 Intens. x10<sup>5</sup> +MS, 0.3min #20 1.25 1.00 401.1950 0.75 0.50 0.25 0.00 398 394 400 392 396 402 404 406 408 m/z Sum Formula Sigma m/z Err [ppm] Mean Err [ppm] Err [mDa] C 21 H 30 Na 1 O 6 0.004 401.1935 -3.93 -1.93 -1.58 rdb N Rule 6.50 ok even Page 1 of 1 Bruker Daltonics DataAnalysis 3.4 printed: 7/11/2014 3:34:15 PM


#### **S48.** HRESIMS spectrum of (2*S*, 3a*S*)-humulone C (7).

**S49.** Structures and populations of the low-energy B3LYP/6-31G (d) in *vacuo* conformers (>2%) of (2*S*, 3a*S*)-7.




**S50.** <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).






**S51.** <sup>13</sup>C NMR (150 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).


**S52.** HSQC (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).






**S53.** HMBC (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).

**S54.** NOESY (600 MHz, CD<sub>3</sub>OD) spectrum of (3*S*, 3'*R*, 5*R*)-humulone acid B (8).








S56. Selected structures and population of the low-energy B3LYP/6-31G (d) in vacuo


conformers of (3S, 3'R)-8 based on experimental NOE correlations.




Conf. B 21.1 %




S57. The molecular energy profiles of conformational flexibility of compound 8




**S58.** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).






**S59.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of (R)-lupulone H (**9a**).


**S60.** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of (*S*)-lupulone H (**9b**).






**S61.** <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).


S62. HSQC (600 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).







**S63.** HMBC (600 MHz, CDCl<sub>3</sub>) spectrum of lupulone H (9).


**S64.** NOESY (600 MHz,  $CDCl_3$ ) spectrum of lupulone H (9).









**S66.** The HPLC of chiral column analysis of lupulone H (9).




**S67.** Structures and populations of the low-energy B3LYP/6-31G (d) in *vacuo* conformers (>2%) of (2*S*)-9.




**S68.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of lupulone G (10)






**S69.** <sup>1</sup>H NMR (600 MHz, DMSO- $d_6$ ) spectrum of (*R*)-lupulone G (10a)


**S70.** <sup>1</sup>H NMR (600 MHz, DMSO- $d_6$ ) spectrum of (S)-lupulone G (10b)






**S71.** <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of lupulone G (10).


**S72.** Experimental CD spectrum of (*R*)-lupulone G (10a) and (*S*)-lupulone G (10b).




**S73.** The HPLC of chiral column analysis of lupulone G (10).




**S74.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of 5-deprenyllupulonol C (11).






S75. <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of 5-deprenyllupulonol C (11).


**S76.** Experimental CD spectrum of (*R*)-5-deprenyllupulonol C (**11a**) and (*S*)-5-deprenyllupulonol C (**11b**).




S77. The HPLC of chiral column analysis of 5-deprenyllupulonol C (11).




**S78.** <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).




**S79.** <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (**12**).




5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).





5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).



**S82.** HRESIMS spectrum of 5,7-dihydroxy-2-isopropyl-8-prenylchromone (12).

**\$83.** The experimental method used for ECD calculations of compounds 1, 4, 5, 7, 8 and 9

Mean Err [ppm] -0.01

290

Err [ppm]

300

Err [mDa]

310

rdb N Rule

7.50

320

even

m/z

280

C17H21O4

ula Sigma m/z 4 0.052 289.1434

All structures were established by Schrodinger 2013 package. Conformational searches were performed using the bioactive search function of conformational search protocol of the Schrodinger 2013 package with 50 target conformers. The conformers generated from conformational search were optimized at the B3LYP/6-31G (d) level using Gaussian09 package. The optimized conformers were aligned using the flexible ligand alignment protocol to examine if there were identical conformers for some structurally similar conformers would lead to the totally identical conformer after structure optimization. After merging the identical conformers, the remaining conformers were subjected to frequent analysis at the B3LYP/6-31G (d) level and the population of each conformer was determined based on Boltzmann distribution. For compound 7 and 9, eight conformers that contributes over 2 % of the population were used for ECD calculation. For compounds with high flexibility, the geometries from


the conformational searches studies would not represent the real geometries in the solution. Whereas NOE correlations were tested in liquid environments, giving more detailed information of a stereo-structure. Thus, for compounds 1, 4 and 5, the optimized geometries were subjected to intensive NOE analysis for the relative location of the isopentenyl at C-8 versus C-2'/C-1' of 1 and isopentenyl at C-7 versus the  $-C(CH_3)_2OH$  group at C-2 of 4 and 5 could predominate the ECD curves as the isopentenyl at C-8 was a large group besides the chromophore composed of C-8a, 4a, 5, 6, 7 in compound 1 (C-3a, 7a, 4, 5, 6 in compound 4 and 5). The geometries that did not match the experimental NOE correlations were excluded for ECD calculations and finally 6 conformers for 1 and 4 (4 conformers for compound 5) were used for further ECD calculation. For compound 8, the conformational flexibility of the molecule was depicted in the molecular energy profiles (Figure S57 Supporting Information) with respect to the dihedral angle C2'-C3'-C3-C2, ranging from -180° to 180° at the B3LYP/6-31G(d) level of theory. As can be seen from Figure S57, the most stable conformer is obtained for 170° having energy of -1072.13358515 Hartree. Keeping C2'-C3'-C3-C2 at 170°, the conformer of lowest energy  $(170^{\circ})$  was used to perform conformational search, structure optimization and identical conformer merging studies by the same way as compounds 1, 4, 5, 7 and 9 did and finally 3 conformers were generated for ECD calculation. ECD computations for all conformers were carried out at the B3LYP/6-31G (d) level in the gas phase. The calculated ECD spectrums were visualized and Boltzmann averaged using specdis software<sup>1-3</sup>.

## REFERENCES

(1) Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Pecitelli, G. Berlin. Germany, 2017.

(2) Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Bringmann, G. Chirality. 2013, 25, 243-249.

(3) Pescitelli, G.; Bruhn, T. Chirality. 2016, 28, 466-47.



**S84.** BV-2 cell viability assay and effect of the extracts and isolated compounds **1-8**,

## 13-17 on LPS-induced NO production in BV-2 microglial cells.

